Bank of New York Mellon Corp Sells 53,992 Shares of The Chemours Company $CC

Bank of New York Mellon Corp lessened its holdings in The Chemours Company (NYSE:CC) by 3.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 1,610,298 shares of the specialty chemicals company’s stock after selling 53,992 shares during the period. Bank of New York Mellon Corp’s holdings in Chemours were worth $35,475,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the stock. SG Americas Securities LLC grew its holdings in shares of Chemours by 478.4% during the fourth quarter. SG Americas Securities LLC now owns 236,236 shares of the specialty chemicals company’s stock worth $2,785,000 after purchasing an additional 195,393 shares during the last quarter. Vanguard Group Inc. lifted its position in Chemours by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 17,920,868 shares of the specialty chemicals company’s stock worth $211,287,000 after buying an additional 490,778 shares in the last quarter. Versor Investments LP acquired a new position in Chemours during the 4th quarter worth about $314,000. Penn Capital Management Company LLC grew its holdings in Chemours by 113.0% during the 4th quarter. Penn Capital Management Company LLC now owns 1,386,819 shares of the specialty chemicals company’s stock worth $16,366,000 after acquiring an additional 735,668 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in Chemours by 19.9% during the 4th quarter. Legal & General Group Plc now owns 2,139,617 shares of the specialty chemicals company’s stock worth $25,226,000 after acquiring an additional 355,074 shares during the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CC has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Chemours in a research note on Friday, July 17th. UBS Group increased their price target on shares of Chemours from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Morgan Stanley upped their price objective on Chemours from $17.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, May 11th. Alembic Global Advisors reiterated an “overweight” rating and issued a $30.00 price objective on shares of Chemours in a research report on Wednesday, May 13th. Finally, JPMorgan Chase & Co. lifted their target price on Chemours from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Chemours has an average rating of “Moderate Buy” and an average price target of $24.10.

Chemours Stock Performance

Shares of CC stock opened at $17.25 on Monday. The stock has a 50-day moving average of $20.35 and a 200-day moving average of $19.92. The Chemours Company has a one year low of $10.44 and a one year high of $28.67. The stock has a market cap of $2.59 billion, a PE ratio of -6.53 and a beta of 1.41. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.82 and a quick ratio of 0.87.

Chemours (NYSE:CC) last issued its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.10. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The firm had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter in the previous year, the company earned $0.13 earnings per share. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. As a group, sell-side analysts expect that The Chemours Company will post 1.18 earnings per share for the current year.

Chemours Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Sunday, May 17th were issued a $0.0875 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.35 annualized dividend and a dividend yield of 2.0%. Chemours’s payout ratio is -13.26%.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks Research upgraded Chemours (CC) from Hold to Strong Buy, signaling stronger confidence in the company’s outlook. 3 Stocks Worth Buying After Recent Broker Ratings Upgrade
• Positive Sentiment: Analysts also raised longer-term earnings forecasts, including FY2028 EPS to $2.38 from $2.36, suggesting better profit potential over time.
• Positive Sentiment: Zacks lifted its Q4 2027 EPS estimate to $0.53 from $0.50 and increased its Q2 2028 estimate to $0.61 from $0.60, reinforcing a more constructive view on future performance.
• Neutral Sentiment: Chemours announced it will release second-quarter 2026 results after the market closes on August 4, which keeps investors focused on the upcoming earnings report. Chemours Announces Dates for Second Quarter 2026 Earnings Release and Webcast Conference Call
• Negative Sentiment: Zacks trimmed its Q1 2027 EPS estimate to $0.39 from $0.41 and Q3 2027 to $0.56 from $0.57, showing that not all near-term expectations are improving.

Chemours Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.